Proteomics of the Oxidative Phosphorylation System in AD

About the Research Project
Program
Award Type
Standard
Award Amount
$100,000
Active Dates
April 01, 2005 - March 31, 2008
Grant ID
A2005271
Summary
A reduced rate of brain metabolism is one of the best documented abnormalities in Alzheimer’s disease (AD). Since abnormalities in mitochondrial energy production appear to play a major role in pathophysiology of AD, Dr. Breen plans to test the hypothesis that the proteins of the mitochondrial oxidative phosphorylation system are decreased or modified in the brains of AD patients. If data using a mouse model of AD demonstrate differences in the levels of the proteins of the oxidative phosphorylation system in AD versus control brains, then future studies will be directed towards examining these proteins in human AD brains. Identification of the factors involved in the etiology and/or progression of AD may lead to the development of treatments to improve neuropsychological function in AD patients or delay the onset of the disease.
Grants
Related Grants
Alzheimer's Disease Research
Partnership with Molecular Neurodegeneration Open Access Journal
Active Dates
July 01, 2010 - June 30, 2015
Principal Investigator
Guojun Bu, PhD
Partnership with Molecular Neurodegeneration Open Access Journal
Active Dates
July 01, 2010 - June 30, 2015

Principal Investigator
Guojun Bu, PhD
Alzheimer's Disease Research
Synergistic Effects of Biological Sex and Sleep Loss in an AD Mouse Model
Active Dates
January 01, 2025 - December 31, 2026
Principal Investigator
Mallar Chakravarty, PhD
Synergistic Effects of Biological Sex and Sleep Loss in an AD Mouse Model
Active Dates
January 01, 2025 - December 31, 2026
Principal Investigator
Mallar Chakravarty, PhD
Alzheimer's Disease Research
Regulatory Mechanisms Underlying Endosomal Targeting of SORL1
Active Dates
January 01, 2025 - December 31, 2026
Principal Investigator
Olav Andersen, PhD
Regulatory Mechanisms Underlying Endosomal Targeting of SORL1
Active Dates
January 01, 2025 - December 31, 2026

Principal Investigator
Olav Andersen, PhD